Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow REGENEREX PHARMA, INC.

Get SEC filing alerts via email and in your feed for REGENEREX PHARMA, INC.

RGPX

REGENEREX PHARMA, INC.

About REGENEREX PHARMA, INC.

Regenerex Pharma, Inc. develops advanced wound care products utilizing proprietary technologies to treat chronic, acute, and contaminated wounds. Its core offerings include wound closure systems, topical creams, and dressings aimed at improving healing outcomes. Serving healthcare providers, government programs, and international markets, the company emphasizes innovative biotech solutions, clinical efficacy, and strategic partnerships to capture significant market share in wound management.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from REGENEREX PHARMA, INC.

1
1
REGENEREX PHARMA, INC. Regenerex Pharma Reports Increased Losses and Deteriorating Financial Position in Latest Filing

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
REGENEREX PHARMA, INC. Regenerex Pharma Reports Increased Net Loss and Decreased Assets for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
REGENEREX PHARMA, INC. Regenerex Pharma Reports $2.53 Million Net Loss, Seeks Funding to Sustain Operations

Via official filing (AI summary) | 12 months ago | 0 comments

4
1
REGENEREX PHARMA, INC. Regenerex Pharma Reports $1.1 Million Net Loss, Focuses on Wound Care Market Expansion

Via official filing (AI summary) | over 1 year ago | 0 comments

5
1
REGENEREX PHARMA, INC. Regenerex Pharma Reports Improved Financial Performance, Reduced Losses in First Half of Fiscal 2024

Via official filing (AI summary) | over 1 year ago | 0 comments